Compare
Axalta Coating Systems Ltd. vs Huntsman Corp vs Idexx Laboratories Inc vs Jazz Pharmaceuticals plc
| Latest fiscal year | Axalta Coating Systems Ltd. AXTA | Huntsman Corp HUN | Idexx Laboratories Inc IDXX | Jazz Pharmaceuticals plc JAZZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.12B | $5.68B | $4.30B | $4.27B |
| Revenue growth (YoY) | -3.0% | -5.8% | +10.4% | +4.9% |
| Gross margin | 34.4% (computed) | 13.2% | 61.8% | n/a |
| Operating margin | 14.4% | -2.3% | 31.6% | -10.1% |
| Net margin | 7.4% | -5.0% | 24.6% | -8.3% |
| Net income | $378.00M | -$284.00M | $1.06B | -$356.15M |
| EPS (Diluted) | $1.74 | -$1.65 | $13.08 | -$5.84 |
| Operating cash flow | $649.00M | $289.00M | $1.18B | $1.36B |
| Free cash flow | $453.00M | $116.00M | $1.06B | $1.30B |
| Cash & equivalents | $657.00M | $429.00M | $180.07M | $1.39B |
| Total assets | $7.60B | $7.01B | $3.35B | $11.66B |
| Total liabilities | $5.21B | $4.06B | $1.75B | n/a |
| Shareholders' equity | $2.39B | $2.96B | $1.61B | $4.32B |
| Return on year-end equity | 15.8% | -9.6% | 66.0% | -8.2% |
| Shares outstanding | n/a | 172.62M | 79.71M | 61.44M |
Revenue, most recent five fiscal years
| Fiscal year | Axalta Coating Systems Ltd. | Huntsman Corp | Idexx Laboratories Inc | Jazz Pharmaceuticals plc |
|---|---|---|---|---|
| Latest | $5.12B Ended 2025-12-31 | $5.68B Ended 2025-12-31 | $4.30B Ended 2025-12-31 | $4.27B Ended 2025-12-31 |
| 1 year earlier | $5.28B Ended 2024-12-31 | $6.04B Ended 2024-12-31 | $3.90B Ended 2024-12-31 | $4.07B Ended 2024-12-31 |
| 2 years earlier | $5.18B Ended 2023-12-31 | $6.11B Ended 2023-12-31 | $3.66B Ended 2023-12-31 | $3.83B Ended 2023-12-31 |
| 3 years earlier | $4.88B Ended 2022-12-31 | $8.02B Ended 2022-12-31 | $3.37B Ended 2022-12-31 | $3.66B Ended 2022-12-31 |
| 4 years earlier | $4.42B Ended 2021-12-31 | $7.67B Ended 2021-12-31 | $3.22B Ended 2021-12-31 | $3.09B Ended 2021-12-31 |